Clinical Trial Update: Intravenous n-3 Fatty Acids and Sudden Cardiac Death in Hemodialysis Patients [Phase 2]

View source ↗

Summary

This update notes the completion of a Phase 2 trial evaluating intravenous n-3 fatty acids to reduce sudden cardiac death in hemodialysis patients with chronic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• Intravenous n-3 Fatty Acids (n-3 fatty acids (intravenous))

Snippet

Sponsor: Aalborg University Hospital | Conditions: Renal Failure, Chronic | Phase 2 | Status: COMPLETED